Compare Danaher Corporation (DHR) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Plby Group Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Danaher Corporation is far larger — about 1293.2× Plby Group Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Plby Group Inc for 24 Days on average.
| DHR | PLBY | |
|---|---|---|
Market Cap | $152.87B | $118.21M |
Volume | 5,228,698 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $2.71 |
52-Week Low | $161.91 | $0.98 |
Typical Hold Time | 69 Days | 24 Days |
Enterprise Value | $175.08B | $263.80M |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
PLBY trades at $0.9867, down 3.26% today, amid a bearish technical signal with selling pressure across moving averages. The company reported Q2 2026 EPS of $0.00173, beating expectations, and revenue of $121 million in 2025, with net losses narrowing to $12.67 million. Recent news highlights leadership appointments aimed at driving brand growth. Analyst consensus is 75% buy, but high debt and negative equity pose fundamental risks.
Outlook remains cautious due to persistent losses and leveraged balance sheet, though cost controls and licensing growth offer potential upside. Key risks include execution on profitability, competitive pressures, and sensitivity to consumer spending. Investors should weigh analyst optimism against structural financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
